Khandelwal Laboratories Ltd. v. Fdc Limited

In the crowded world of pharmaceuticals, where drug names often sound alike and chemical compounds dictate branding, trademark battles can turn on the thinnest of margins. A single letter, a family of marks, or the weakness of a generic salt-derived name can be the difference between an injunction and a free pass to market. The clash between Khandelwal Laboratories and FDC Limited over the marks CEFI and ZIFI is a textbook example of how courts weigh phonetic similarity against the broader realities of the pharmaceutical marketplace.

Khandelwal Laboratories, the plaintiff, claimed ownership of the trademark CEFI and sought to protect it from what it alleged was a deceptively similar mark, ZIFI, used by FDC Limited, the defendant. Khandelwal had secured an ex-parte injunction, a court order granted without hearing the defendant, which temporarily restrained FDC from using the ZIFI mark. The dispute centered on whether ZIFI was deceptively similar to CEFI, given that the two names sounded remarkably alike when spoken aloud. FDC, however, came prepared with a different narrative, one built around a family of 'Z' trademarks and the inherent weakness of pharmaceutical marks derived from generic chemical salts.

Khandelwal Laboratories argued that the phonetic similarity between CEFI and ZIFI was sufficient to confuse consumers and constitute passing off, the legal wrong of misrepresenting one's goods as those of another. The plaintiff leaned heavily on the near-identical sound of the two marks to justify the ex-parte injunction. FDC Limited countered with a multi-pronged defense. First, the defendant pointed to its established family of 'Z' trademarks, suggesting that the distinctive 'Z' prefix set its brand apart and was a recognizable signature in the market. Second, FDC argued that pharmaceutical marks derived from generic chemical salts are inherently weak and entitled to a narrower scope of protection, meaning that minor phonetic overlaps should not automatically trigger infringement findings. The legal friction thus centered on whether phonetic similarity alone could outweigh the distinctiveness of the 'Z' prefix and the weakness of salt-derived pharmaceutical names.

The Delhi High Court sided with FDC Limited and vacated the ex-parte injunction that had restrained the defendant from using the ZIFI mark. The court acknowledged the phonetic similarity between CEFI and ZIFI but found that this factor alone was not decisive. The defendant's family of 'Z' trademarks provided a meaningful point of distinction, and the weakness of pharmaceutical marks derived from generic chemical compounds meant that the plaintiff's CEFI mark was entitled to only limited protection. Applying the balance of convenience, the court's test for weighing which party would suffer greater harm from the grant or denial of an injunction, the court ruled in favor of FDC, allowing the defendant to continue using its ZIFI mark.

For founders and IP professionals in the pharmaceutical space, this case delivers a clear lesson: phonetic similarity is just one piece of the trademark puzzle. When building a brand around a chemical compound or salt-derived name, expect a narrower scope of protection and prepare for crowded marketplaces where similar-sounding marks are common. Invest in distinctive branding elements, such as a strong, recognizable prefix like 'Z', and cultivate a family of marks to reinforce your identity. Most importantly, do not assume that an ex-parte injunction will hold; courts will weigh the balance of convenience carefully, and the weakness of your mark may work against you when seeking to block a competitor.